NSE filing, NSE: ZYDUSLIFE. Summary written from the filing by ALFA Finder's alert engine.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,199.70
- Market cap
- ₹1,20,718 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.8×Sector 41.3×
- Promoter holding
- 75.01%+0.00% QoQ
- FII holding
- 7.05%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Investor Presentation: Key Takeaways
Q2 FY27 revenue Rs 7,910 Cr (+29% YoY), EBITDA Rs 1,895 Cr at 24.0% margin, reported PAT Rs 926 Cr (-26.6% YoY). Branded India and North America drove growth; FX and D&A weighed on profit.
Zydus Lifesciences Other Announcement
Zydus Lifesciences board approved appointment of Walker Chandiok & Co LLP as statutory auditors for a five-year term. This follows mandatory rotation of outgoing auditor Deloitte Haskins and Sells LLP.
Zydus Lifesciences Q2 FY27 Results: Net Profit ₹925.5 Cr, Down 26.6% YoY
Zydus Lifesciences Ltd reported revenue from operations of ₹7,910 Cr (+29.2% YoY) and net profit of ₹925.5 Cr (-26.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹925.5 Cr · -26.6% YoY
Zydus Lifesciences Acquisition Worth ₹84 Cr
Zydus Lifesciences acquired Sterling Biotech's API business for Rs. 84 Crore via slump sale. The deal covers fermentation-based API products and is completed.
- Value
- ₹84.00 Cr
Zydus Lifesciences Acquisition Worth ₹167 Cr
Zydus Lifesciences completed acquisition of Sterling Biotech's API business for Rs. 167 Crore. The slump sale of fermentation-based API products strengthens its manufacturing portfolio.
- Value
- ₹167.0 Cr
Zydus Lifesciences Acquisition
Zydus Lifesciences completed its acquisition of Sterling Biotech's API business under a September 2024 Business Transfer Agreement. No transaction value was disclosed in this filing.
Other results update announcements
All →Redington Results Update
Redington reports Q2 FY27 revenue of ₹43,002 crore, up 48% YoY, with PAT of ₹581 crore. Growth led by India revenue (+67%) and Technology Solutions Group (+91%).
Jyothy Labs Results Update
Jyothy Labs posted Q2 FY27 revenue of ₹760 crore and PAT of ₹10.6 crore. H1 FY27 revenue reached ₹1,533 crore with PAT of ₹58.2 crore amid margin pressure.
Ecoplast Results Update
Ecoplast Q2 FY27 revenue grew 36% to ₹73.93 crore, but PAT fell 67% to ₹0.78 crore. A new greenfield plant became operational in October 2026.
Marksans Pharma Results Update
Marksans Pharma reported Q2FY27 revenue of ₹940 crore and H1FY27 PAT of ₹303 crore. EBITDA grew 48% to a record ₹214 crore in the quarter.
Rajshree Polypack Results Update
Rajshree Polypack reported Q2 FY27 revenue of ₹102.90 Cr, up 19.06% YoY, and PAT of ₹5.02 Cr. Half-year PAT rose 40.87% YoY to ₹12.27 Cr.
Biocon Results Update
Biocon reported Q2FY27 consolidated total income of ₹4,423 crore with EBITDA at ₹865 crore. Net profit was ₹41 crore as Biopharma revenue grew 5% YoY.